6-iodo-5-(4-(2-methoxyethoxy)-4-(1H-tetrazol-5-yl)cyclohexyl)-3-(1-phenyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7-amine | 1361450-79-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 6-iodo-5-(4-(2-methoxyethoxy)-4-(1H-tetrazol-5-yl)cyclohexyl)-3-(1-phenyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7-amine
• 英文别名: 6-iodo-5-[4-(2-methoxyethoxy)-4-(2H-tetrazol-5-yl)cyclohexyl]-3-(1-phenylpyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7-amine
• CAS: 1361450-79-4
• 化学式: C₂₅H₂₇IN₁₀O₂
• 分子量: 626.46
• InChiKey: OFLPICNDVXRKRS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  38
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  147
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• [EN] NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS DE PYRAZOLO[1,5-A]PYRIMIDINE UTILISÉS COMME INHIBITEURS DE MTOR
  申请人：SCHERING CORP

  公开号：WO2012027236A1

  公开（公告）日：2012-03-01

  The present invention relates to certain pyrazolo[1,5-a]pyrimidine compounds of Formula (I) as inhibitors of mammalian Target Of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP. The compounds may be used in the treatment of cancer and other disorders where mTOR is deregulated. The present invention further provides pharmaceutical compositions comprising the pyrazolo[1,5-a]pyrimidine compounds.

  本发明涉及某些吡唑并[1,5-a]嘧啶化合物，其化学式为(I)，作为哺乳动物雷帕霉素靶蛋白(mTOR)激酶的抑制剂，也称为FRAP、RAFT、RAPT或SEP。这些化合物可用于治疗癌症和其他mTOR调节异常的疾病。本发明还提供了包含吡唑并[1,5-a]嘧啶化合物的药物组合物。
• NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
  申请人：Zhao Lianyun

  公开号：US20130150362A1

  公开（公告）日：2013-06-13

  The present invention relates to certain pyrazolo[1,5-a]pyrimidine compounds of Formula (I) as inhibitors of mammalian Target Of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP. The compounds may be used in the treatment of cancer and other disorders where mTOR is deregulated. The present invention further provides pharmaceutical compositions comprising the pyrazolo[1,5-a]pyrimidine compounds.

  本发明涉及某些嘧唑并[1,5-a]嘧啶化合物（式（I）），作为哺乳动物雷帕霉素靶（mTOR）激酶的抑制剂，该激酶也被称为FRAP、RAFT、RAPT或SEP。这些化合物可用于治疗癌症和其他mTOR失调的疾病。本发明还提供了包含嘧唑并[1,5-a]嘧啶化合物的药物组合物。
• US8883801B2
  申请人：——

  公开号：US8883801B2

  公开（公告）日：2014-11-11